After amyloid: why tau tracks Alzheimer's symptoms more closely
- Richard Moore
- 3 days ago
- 13 min read
For decades, Alzheimer's research has been dominated by a single villain: amyloid-beta, the sticky protein that clumps into plaques in the brain. Drug after drug was designed to attack it. And now, finally, two amyloid-clearing antibodies, lecanemab and donanemab, have reached clinics, offering the first treatments that genuinely modify how the disease progresses rather than merely managing symptoms (Sabbagh et al., 2024; Lim et al., 2026). It is a genuine milestone.
But here is the paradox that scientists have quietly wrestled with for years: clearing amyloid slows the disease only modestly, and the level of amyloid in a person's brain tells you surprisingly little about how confused or forgetful they actually are right now. A person can have a brain packed with plaques and remain cognitively sharp. Conversely, people with similar amyloid burdens can have markedly different levels of cognitive impairment.
Amyloid appears to help initiate or enable the disease process, while the location and extent of tau pathology more closely reflect neurodegeneration and clinical symptoms. That is where scientific attention is increasingly turning.
Two proteins, two very different stories
Think of the brain as a city, and its neurones as an elaborate network of delivery roads. Each neurone contains tiny internal railways called microtubules, which shuttle nutrients and signals up and down the cell. Tau is the protein that acts like the railway sleepers, the structural ties that hold those tracks together (Barbier et al., 2019).
In a healthy brain, tau does its job quietly. In Alzheimer's disease, tau gets chemically modified through a process called hyperphosphorylation, where too many phosphate tags attach to it, causing it to detach from the microtubules, misfold, and clump into twisted knots called neurofibrillary tangles (Macedo et al., 2023). When this happens, the internal railways collapse. The neurone can no longer transport what it needs to survive.
Here is the critical difference between amyloid and tau. Amyloid plaques begin accumulating in the brain 20 to 30 years before any symptoms appear (Therriault et al., 2024). By the time someone visits a memory clinic, their amyloid burden may have already plateaued. This is why amyloid correlates so poorly with how someone actually feels day to day; the plaques have been present for decades, long before any cognitive complaint.
Tau changes can begin earlier in medial-temporal regions, but widespread neocortical tau generally develops closer to symptom onset and tracks subsequent decline more closely (Therriault et al., 2024). Its spread maps the unfolding of the disease almost like a navigator, telling you not just where the damage has been but where it is heading next.
The Braak Map: reading the route of the disease
In the early 1990s, neuropathologists Heiko and Eva Braak made a striking observation in post-mortem brain tissue: tau tangles did not appear randomly. They followed a highly predictable path through the brain, consistent enough to be used to stage the disease (Macedo et al., 2023).
This sequence, now known as Braak staging, begins in the entorhinal cortex, a region critical for memory, before spreading to the hippocampus, then outward to association cortices, and eventually the neocortex (Macedo et al., 2023). The progression maps almost perfectly onto the typical symptom journey: first, short-term memory loss (hippocampal involvement), then difficulties with planning and language (frontal and temporal spread), and finally the profound disorientation seen in late-stage disease.
Amyloid spreads in a different pattern that does not align nearly as well with the clinical picture. Multiple studies and post-mortem examinations have confirmed that the extent of neurofibrillary tau tangles correlates far more strongly with cognitive impairment than amyloid plaques do (La Joie et al., 2020; Therriault et al., 2024). A large imaging study found that tau positron emission tomography (PET) scans significantly outperformed amyloid PET in predicting future cognitive decline (Biel et al., 2021).
A useful analogy: amyloid is like a thunderstorm that starts building over a city decades before it rains. By the time you feel the first drops, the first symptoms, the storm has been building so long that checking the clouds barely tells you how wet you are about to get. Tau is the rainfall itself: it tells you where water is falling right now, and which streets are already flooded.
Amyloid-clearing drugs: a real advance, but not the full story
The approval of lecanemab in 2023 and donanemab in July 2024 marked the end of a 17-year drought in which no truly disease-modifying Alzheimer's drug existed (Cummings et al., 2024; Sabbagh et al., 2024). Lecanemab targets an early, particularly toxic form of amyloid called protofibrillar amyloid-beta, disrupting it before it can cause further damage (Kandeel et al., 2025). In its pivotal CLARITY-AD trial, it slowed cognitive and functional decline by around 27% over 18 months (Lim et al., 2026). Donanemab achieved even more dramatic amyloid clearance in the TRAILBLAZER-ALZ 2 trial (Lim et al., 2026; Sabbagh et al., 2024). But researchers have noted something telling in the data: even after clearing substantial amyloid, cognitive benefit is modest rather than transformative. Removing amyloid does not remove established tau tangles, and cognitive decline can continue despite substantial plaque clearance (Blennow & Zetterberg, 2024). Once tau pathology is established, it appears to take on a life of its own, like falling dominoes that keep toppling even after the initial push has gone.
Both drugs also carry real risks. They can cause a side effect called amyloid-related imaging abnormalities (ARIA), meaning tiny bleeds or swelling in the brain, which are mostly asymptomatic but require careful magnetic resonance imaging (MRI) monitoring (Lim et al., 2026). These are early-stage treatments in specialist settings, not yet widely accessible.
This does not diminish their importance for those who qualify. But the field increasingly recognises that amyloid clearance alone is unlikely to be the complete answer, and that tau demands its own therapeutic strategy.
The race to target tau directly
If tau more faithfully tracks symptoms, the logical next step is to target it directly. A first wave of anti-tau antibodies, including semorinemab, gosuranemab, tilavonemab, and zagotenemab, were tested in clinical trials. All failed to demonstrate meaningful clinical benefit in early Alzheimer's disease (Cai et al., 2025; Teng et al., 2022).
This was disappointing but illuminating. These antibodies targeted the amino-terminal end of the tau protein, essentially its starting section, one specific region. Removing circulating tau from outside neurones may not be enough if tangles are already well-established inside them. The field has learned from these failures.
Second-generation tau antibodies now target different regions of the protein, particularly a central domain called the microtubule-binding region (MTBR) that is directly involved in aggregation. The tau antibody bepranemab did not meet its primary clinical endpoint in the overall trial population, but encouraging secondary cognitive and tau-PET findings, along with positive results in prespecified subgroups, provided a preliminary signal warranting further study (Cowan et al., 2025). It is early-stage evidence, but it represents the most promising step yet in the search for a tau-targeting therapy.
The nutritional therapy and functional medicine Lens: supporting brain health from the inside
Pharmaceutical approaches work downstream, targeting proteins once they have already accumulated. Nutritional therapy and functional medicine ask a different but complementary question: what modifiable contributors to overall brain health can be identified and supported?
It is important to be clear about what this means in practice. Nutritional therapy cannot remove amyloid or stop tau spread. What it can do is help identify and manage potentially modifiable factors that may contribute to brain vulnerability, including nutritional deficiencies, metabolic and vascular risk, poor sleep, gut health, and medication-nutrient interactions. Used alongside specialist medical care, this is a clinically meaningful role.
The metabolic connection
The phrase "Type 3 Diabetes" is sometimes used in research to describe the insulin-signalling abnormalities observed in Alzheimer's disease, where neurons appear less able to use glucose efficiently (Pugazhenthi et al., 2017). It is not a recognised clinical diagnosis, and Alzheimer's is not simply diabetes of the brain, but the observation points to a genuine overlap between metabolic health and neurodegeneration that is worth taking seriously. (We have explored this concept in much greater depth in our previous blog, Diabetes 3.0: why your brain might be quietly starving in a sea of sugar, which is well worth reading alongside this one.)
Research suggests that insulin resistance may promote tau hyperphosphorylation, turning up the very process that causes tau to misfold (Pugazhenthi et al., 2017; Zhang et al., 2026). Addressing cardiometabolic risk through dietary change is therefore a reasonable supportive strategy, though it is important to note that no dietary intervention has been shown in clinical trials to directly reduce tau pathology in humans.
Dietary patterns and brain health
A five-year prospective cohort study tracking Mediterranean and MIND (Mediterranean-DASH Intervention for Neurodegenerative Delay) diet adherence found both associated with better cognitive outcomes and markers of lower neuroinflammation (Zhang et al., 2025). These are observational associations rather than proof of treatment effect, but they are consistent with a broader evidence base supporting these dietary patterns for cardiovascular and metabolic health, which in turn may support brain resilience.
Specific nutrients appear particularly relevant. Polyphenols, found in berries, dark leafy greens, olive oil, and green tea, have been shown in preclinical and some clinical work to reduce oxidative stress and support the signalling pathways involved in cellular housekeeping (Arora et al., 2025).
Omega-3 fatty acids, particularly docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) from oily fish, are important for maintaining cell membrane integrity and have anti-inflammatory properties (De Marchi et al., 2024). A narrative review and analysis of existing omega-3 trials concluded that the evidence remains mixed and that there is a strong case for personalised assessment and supplementation based on individual status and genetic profile rather than blanket high-dose recommendations (Castellanos-Perilla et al., 2024).
B vitamins, particularly B12 and folate, are clinically important because deficiency in either can contribute directly to cognitive symptoms. Testing and correcting deficiency is standard nutritional practice. Routine high-dose B-vitamin supplementation has not been established as a treatment for Alzheimer's disease, but ensuring sufficiency is a reasonable and evidence-supported baseline (De Marchi et al., 2024).
The gut-brain axis and neuroinflammation
Chronic neuroinflammation is increasingly understood as a driver of tau pathology, and the gut-brain axis is emerging as one possible regulator of that inflammatory tone (De Marchi et al., 2024). Microbiome changes and impaired intestinal-barrier function are being investigated as possible contributors to systemic inflammation, but their causal importance in human Alzheimer's disease, and the effectiveness of microbiome-directed interventions, remain areas of active and ongoing research rather than established clinical fact.
This is precisely the territory that the Bredesen Protocol and its associated ReCODE (Reversal of Cognitive Decline) framework were designed to address. Developed by neurologist Dr Dale Bredesen following decades of laboratory research into the mechanisms of neurodegeneration, ReCODE takes a personalised, root-cause approach to cognitive health. Rather than targeting a single pathway, it maps each individual's unique contributors to brain vulnerability, spanning metabolic function, gut health, hormone balance, nutritional status, sleep quality, chronic infections, and toxin exposure, and builds a tailored plan to address them (Rao et al., 2023).
What makes this approach so aligned with emerging science is its recognition, long before it entered the mainstream, that Alzheimer's disease is not a single-cause condition. The very biological drivers that ReCODE addresses, insulin resistance, neuroinflammation, nutrient deficiency, and gut dysbiosis, are now being confirmed by independent research as meaningful contributors to disease progression. A peer-reviewed analysis of participants in the ReCODE programme found that the majority experienced stabilisation or improvement in cognitive function, with those entering the programme at earlier stages showing the strongest outcomes (Rao et al., 2023). A formal randomised controlled trial is currently underway to test the protocol's effects with the rigour the scientific community rightly expects.
It is worth being clear that ReCODE is not a cure for Alzheimer's disease, and it works best as a complement to specialist medical care rather than a replacement for it. But for individuals who want to take an active, evidence-informed role in their brain health, and who want support from a practitioner who understands the full biological picture, it offers something that pharmaceutical treatment alone cannot: a comprehensive strategy for the terrain in which the disease either takes hold or struggles to advance.
Your brain's overnight clean-up
Perhaps the most fascinating area of recent Alzheimer's research has nothing to do with drugs. It concerns what your brain does while you sleep.
The brain has its own lymphatic drainage system, called the glymphatic system, a network of fluid-filled channels that runs alongside blood vessels. During deep, slow-wave sleep, this system becomes dramatically more active, flushing the brain with cerebrospinal fluid and washing away accumulated waste, including both amyloid-beta and tau (Dagum et al., 2026; Zare et al., 2026). (For a deep dive into how this system works and its implications across Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis (ALS) / motor neurone disease (MND), see our previous blog: The brain's hidden cleaning system: how night-time detox could hold clues to Alzheimer's, Parkinson's & ALS/MND.)
In 2026, a landmark randomised crossover trial published in Nature Communications provided the first direct human evidence that sleep-active glymphatic clearance significantly increases the overnight removal of both amyloid and tau biomarkers into the bloodstream compared to sleep deprivation (Dagum et al., 2026). When sleep is disrupted, this clearance process is impaired and proteins accumulate.
Think of it as the brain's overnight dishwasher. Skip the cycle, and the debris builds up. Optimising sleep quality is a biologically plausible and clinically important area of supportive care, though trials have not yet established that improving glymphatic clearance slows Alzheimer's progression directly. What is clear is that chronic sleep disruption is a modifiable risk factor worth addressing, and nutritional therapy has practical tools to support it.
Putting it together
The science is pointing somewhere genuinely interesting. Amyloid-targeting drugs have opened a new chapter in Alzheimer's treatment. Emerging tau-targeting therapies represent the next frontier. And an honest, evidence-grounded approach to metabolic health, nutrition, sleep, and gut function represents a meaningful supportive layer that addresses factors pharmaceutical trials cannot reach.
The role of nutritional therapy is not to replace medical treatment or to claim it can clear proteins from the brain. It is to work alongside specialist care, reduce modifiable risk, correct deficiencies, and support the overall biological conditions in which the brain has the best chance of staying resilient for as long as possible. For people in the early stages of concern, that is not a small thing.
Coming next ...
In our next blog, we take a closer look at the tau-targeting trials themselves: what they have tested, what the results actually show, and why this remains a promising direction rather than a proven treatment. If this article has left you curious about what comes after amyloid, that one is for you.
The Tau-Targeting trials: a promising direction, not yet a treatment
Work With Nicolle at You Nutrition Clinic
Nicolle, a ReCODE certified registered nutritional therapy practitioner and memory clinic nurse, specialises in supporting adults with Alzheimer's disease and other forms of dementia, providing personalised nutritional therapy guidance that works alongside conventional medical care to address modifiable contributors to brain health, including nutritional status, metabolic risk, sleep, and gut function.
She also works with individuals who are concerned about memory changes or who wish to reduce their risk of developing dementia, because the evidence is clear that earlier intervention, when the brain still has more resilience to draw on, offers more to work with.
In addition, Nicolle also works with clients who have experienced a traumatic brain injury (TBI) and those living with epilepsy, conditions that share important biological overlaps with the neuroinflammatory and metabolic processes discussed throughout this article.
If you are ready to take a personalised, evidence-informed approach to your brain health, get in touch to find out how Nicolle can support you.
Email Nicolle at nicolle@younutritionclinic.com
Find out more about our services at https://www.younutritionclinic.com/cognitive-health
🧩 Connect with us
For research updates, practical tips, and ongoing inspiration, follow us on Instagram:
👉 @drkirstielawton
Stay curious. Stay hopeful. Support your brain. 🧠
Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. Always consult with a qualified, registered medical doctor (MD) for diagnosis and treatment decisions.
References
Arora, A., Singh, V. P., & Bali, A. (2025). The role of the Mediterranean diet in reducing the risk of cognitive impairment, dementia, and Alzheimer's disease: A meta-analysis. GeroScience. https://doi.org/10.1007/s11357-024-01488-3
Barbier, P., Zejneli, O., Martinho, M., Lasorsa, A., Belle, V., Smet-Nocca, C., Tsvetkov, P. O., Devred, F., & Landrieu, I. (2019). Role of tau as a microtubule-associated protein: Structural and functional aspects. Frontiers in Aging Neuroscience, 11, Article 204. https://doi.org/10.3389/fnagi.2019.00204
Biel, D., Brendel, M., Rubinski, A., Buerger, K., Janowitz, D., Dichgans, M., Franzmeier, N., & Alzheimer's Disease Neuroimaging Initiative. (2021). Tau-PET and in vivo Braak-staging as a prognostic marker in Alzheimer's disease [Preprint]. medRxiv. https://doi.org/10.1101/2021.02.04.21250760
Blennow, K., & Zetterberg, H. (2024). Tau biology, biomarkers, and therapeutics. Alzheimer's & Dementia. https://doi.org/10.1002/alz.13608
Cai, W., Zhang, H., Wu, Y., Yao, Y., & Zhang, J. (2025). Comparative efficacy and safety of gosuranemab, semorinemab, tilavonemab, and zagotenemab in patients with Alzheimer's disease: A systematic review and network meta-analysis of randomised controlled trials. Frontiers in Aging Neuroscience, 16, Article 1465871.
Castellanos-Perilla, N., Borda, M. G., Aarsland, D., & Barreto, G. E. (2024). An analysis of omega-3 clinical trials and a call for personalised supplementation for dementia prevention. Expert Review of Neurotherapeutics. https://doi.org/10.1080/14737175.2024.2313547
Cowan, C. M., Mudher, A., & Hampshire, D. J. (2025). The evolving landscape of Alzheimer's disease therapy: From amyloid-beta to tau. Cell, 188(24), 6780–6810. https://doi.org/10.1016/j.cell.2025.09.032
Cummings, J., Zhou, Y., Lee, G., Zhong, K., Fonseca, J., & Cheng, F. (2024). Alzheimer's disease drug development pipeline: 2024. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 10(2), Article e12465. https://doi.org/10.1002/trc2.12465
Dagum, P., Iliff, J. J., Elbert, D. L., Giovangrandi, L., Singh, T., Venkatesh, V. V., Corbellini, A., Kaplan, R. M., Ludington, E., Yarasheski, K., Lowenkron, J., VandeWeerd, C., & Lim, M. M. (2026). The glymphatic system clears amyloid beta and tau from brain to plasma in humans. Nature Communications. https://doi.org/10.1038/s41467-026-68374-8
De Marchi, F., Vignaroli, F., Mazzini, L., Comi, C., & Tondo, G. (2024). New insights into the relationship between nutrition and neuroinflammation in Alzheimer's disease: Preventive and therapeutic perspectives. CNS & Neurological Disorders: Drug Targets, 23(5), 614–627. https://doi.org/10.2174/1871527322666230608110201
Kandeel, M., Sarkar, A. K., Almotairy, A., Chandrasekaran, B., & Yadav, H. N. (2025). Amyloid solutions: Lecanemab, gantenerumab, and donanemab in the treatment of Alzheimer's disease. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 61, Article 37. https://doi.org/10.1186/s41983-025-00968-3
La Joie, R., Visani, A. V., Baker, S. L., Brown, J. A., Bourakova, V., Cha, J., Chaudhary, K., Edwards, L., Iaccarino, L., Janabi, M., Lesman-Segev, O. H., Miller, Z. A., Perry, D. C., O'Neil, J. P., Pham, J., Rojas, J. C., Rosen, H. J., Miller, B. L., Jagust, W. J., & Rabinovici, G. D. (2020). Prospective longitudinal atrophy in Alzheimer's disease correlates with the intensity and topography of baseline tau-PET. Science Translational Medicine, 12(524), Article eaau5732. https://doi.org/10.1126/scitranslmed.aau5732
Lim, H. B., Gerber, M., Hubbard, I., Charidimou, A., Werring, D. J., & Bhatt, D. L. (2026). Donanemab and lecanemab in Alzheimer's disease treatment: A narrative review of clinical trials and discussion of implications for patient access. Brain and Behavior. https://doi.org/10.1016/S3050840126000383
Macedo, A. C., Tissot, C., Therriault, J., Chamoun, M., Lussier, F., Bezgin, G., Tudorascu, D. L., Benedet, A. L., Ashton, N. J., Blennow, K., Zetterberg, H., Gauthier, S., & Rosa-Neto, P. (2023). The use of tau PET to stage Alzheimer disease according to the Braak staging framework. Journal of Nuclear Medicine, 64(8), 1171–1178. https://doi.org/10.2967/jnumed.122.265200
Pugazhenthi, S., Qin, L., & Reddy, P. H. (2017). Common neurodegenerative pathways in obesity, diabetes, and Alzheimer's disease. Biochimica et Biophysica Acta: Molecular Basis of Disease, 1863(5), 1037–1045. https://doi.org/10.1016/j.bbadis.2016.04.017
Rao, R. V., Subramaniam, K., Gregory, J., Coward, C., Okada, S., Kelly, L., Bredesen, A., & Bredesen, D. E. (2023). Rationale for a multi-factorial approach for the reversal of cognitive decline in Alzheimer's disease and mild cognitive impairment (MCI): A review. International Journal of Molecular Sciences, 24(2), Article 1659. https://doi.org/10.3390/ijms24021659
Sabbagh, M. N., Hendrix, S., Harrison, J. E., Voss, T., Ricci, B., Pappas, V., Yetter, E., & Dunn, I. (2024). What's in it for me? Contextualising the potential clinical impacts of lecanemab, donanemab, and other anti-beta-amyloid monoclonal antibodies in early Alzheimer's disease. Neurology and Therapy, 13(6), 1663–1682. https://doi.org/10.1007/s40120-024-00666-4
Teng, E., Manser, P. T., Pickthorn, K., Brunstein, F., Blennow, K., Boada, M., Bouter, I., Cedarbaum, J. M., & Lasser, R. A. (2022). Safety and efficacy of semorinemab in individuals with prodromal to mild Alzheimer disease: A randomised clinical trial. JAMA Neurology, 79(8), 758–767. https://doi.org/10.1001/jamaneurol.2022.1375
Therriault, J., Iturria-Medina, Y., Bhatt, P., Rodriguez, J. L., Armananzas, R., Thotakuri, S., Vermeiren, M., Tissot, C., Benedet, A. L., Ashton, N. J., Blennow, K., Zetterberg, H., Gauthier, S., & Rosa-Neto, P. (2024). Deconstructing pathological tau by biological process in early stages of Alzheimer disease. eBioMedicine, 102, Article 105043. https://doi.org/10.1016/j.ebiom.2024.105043
Zare, H., Naseri, M., & Hosseini, S. H. (2026). Sleep-dependent clearance of brain metabolites via the glymphatic system: Implications for Alzheimer's pathophysiology. Brain and Behavior, 16(4), Article e71374. https://doi.org/10.1002/brb3.71374
Zhang, N., Chai, S., & Wang, J. (2025). The long-term neuroprotective effect of MIND and Mediterranean diet on patients with Alzheimer's disease. Scientific Reports, 15, Article 40592. https://doi.org/10.1038/s41598-025-17055-5
Zhang, Q., Liu, L., & Li, X. (2026). Exercise suppresses insulin resistance: A potential mechanism for improving the interaction between type 2 diabetes and Alzheimer's disease. Journal of Integrative Neuroscience, 25(1). https://doi.org/10.31083/JIN44389
Comments